2011 Clinical Trials Extraction Strains 
The Cannigma
JUNE 23, 2022
A 2011 in vitro study examined the anti-inflammatory properties of six different cannabinoids, including CBGA. More preclinical research involving cell cultures and animal models are needed, even before human clinical trials can take place to confirm the effects of cannabinoid acids on COVID infection. Pain and inflammation.
Cannabis Law Report
OCTOBER 29, 2019
Safety is imperative for any reputable brand of hemp extract, and we are confident that the dosing we recommend is both safe and effective,” said Dr. Wakshlag, Chief Medical Officer at ElleVet Sciences. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement. Wakshlag, DVM, Ph.D.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 25, 2019
Syqe Medical was founded in 2011 in order to develop a measurable and repeatable method of administering medical cannabis. We don’t manipulate the raw plant; we administer the extract through inhalation because this is the right way in which the product has been consumed for years by 90% of users. It’s very instinctive.
The Cannigma
FEBRUARY 11, 2021
Listen & Subscribe: When Mara Gordon started using medical cannabis there wasn’t any lab testing — or any way to know how much of each cannabinoid or terpene was in a given strain. You know, started doing clinical trials through Zelda Therapeutics, and all the other things I’ve done. How does that process work? Elana: Right.
Green Relief
MAY 13, 2018
As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. A 2011 article in the British Journal of Pharmacology describes the ECS as “a self-protective mechanism” that kicks into high gear in response to a stroke or TBI.
Green Relief
MAY 12, 2018
As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. A 2011 article in the British Journal of Pharmacology describes the ECS as “a self-protective mechanism” that kicks into high gear in response to a stroke or TBI.
Expert insights. Personalized for you.
113 
Let's personalize your content